Pharming PHAR
NASDAQ PHAR
$9.65 -0.10 (-1.03%)
As of: Oct 21, 2026 · 2:25 PM EDT

Pharming (PHAR) EV to EBITDA (2021 - 2026)

Updated

Pharming's (PHAR) EV to EBITDA came in at 36.15 for Q2 2026, down 36.9% from 57.25 a year earlier.

Analysis

Pharming (PHAR) EV to EBITDA (2021 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, EV to EBITDA at Pharming was 6.41, down 5.7% year-over-year; for FY2025, it was 27.66, down 95.9% from FY2024.

  • In prior years, Pharming's EV to EBITDA was 670.78 in FY2024, 52.53 in FY2023 (+322.9%), 12.42 in FY2022 (-21.1%) and 15.75 in FY2021 (+70.3%).
  • The Q2 2026 figure stands as the lowest quarterly EV to EBITDA since Q3 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Pharming 664.67 Mn -129.70 Mn 141.47 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 25.49
Dec 31, 2025 29.25
Jun 30, 2025 29.22
Dec 31, 2024 34.17
Sep 30, 2024 58.72
Dec 31, 2023 36.40
Sep 30, 2023 23.03
Dec 31, 2022 39.68
Sep 30, 2022 15.11
Dec 31, 2021 6.84
API Access

Pharming EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=PHAR&period=max&api_key=YOUR_API_KEY